COSMO PHARMACEUTICALS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.6 CHF | -0.69% |
|
+0.28% | +40.67% |
| Apr. 25 | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
| Mar. 20 | Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 100.84 and 9.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +40.67% | 1.27B | C- | ||
| +26.21% | 653B | C+ | ||
| +27.00% | 556B | B | ||
| -6.62% | 354B | C+ | ||
| +20.47% | 331B | B- | ||
| +2.25% | 296B | C+ | ||
| +13.09% | 233B | B+ | ||
| +5.46% | 201B | B- | ||
| -9.61% | 193B | A+ | ||
| -6.25% | 144B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- COPN Stock
- Ratings Cosmo Pharmaceuticals N.V.
